CRISPR Zugo-cel Shows Promise in Autoimmune Trial
Early data from CRISPR Therapeutics' gene-edited CAR-T therapy show responses across lupus, scleroderma and inflammatory myopathy patients.
Updated on Nov. 8, 2026 in Biotech
CRISPR Therapeutics provided an update on zugo-cel, an investigational gene-edited allogeneic CAR-T cell therapy, in refractory rheumatologic autoimmune diseases. As of October 15, 2026, 21 patients had been dosed across lupus, systemic sclerosis and idiopathic inflammatory myopathy cohorts.
Why it matters
Autoimmune diseases such as lupus and scleroderma often resist standard treatments, so early responses in a small trial draw attention to a different therapeutic approach. The data remain preliminary and come from a limited number of patients.
The interim results come from 21 patients dosed across three cohorts, with five of six systemic sclerosis patients reaching an rCRISS-25 response at Month 3 and all five responders maintaining it. Dose escalation is ongoing, and the number of patients in each cohort is too small to establish efficacy rates with confidence.
The players
CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company headquartered in Zug, Switzerland, developing CRISPR-based therapies for serious diseases.
The details
Zugo-cel is an allogeneic CAR-T therapy targeting CD19 that was gene-edited using CRISPR/Cas9 for targeted knockout and CAR insertion. It is administered after a standard lymphodepletion regimen without HLA matching, and it has been well tolerated in all 21 patients dosed, with no cytokine release syndrome above Grade 2 reported.
Timeline
July 21, 2026: Data cut-off for the systemic sclerosis presentation at ACR Convergence 2026.
October 15, 2026: 21 patients had been dosed across the trial cohorts.
November 8, 2026: CRISPR Therapeutics issued the zugo-cel update press release.
Tech Landscape
Zugo-cel applies the CRISPR/Cas9 gene-editing platform to allogeneic CAR-T cells, extending a technology first used in blood cancer treatment into autoimmune disease. The trial's early results add to a growing body of work testing CAR-T therapy beyond oncology.
For patients living with lupus, scleroderma or inflammatory myopathy, zugo-cel remains investigational and is not yet available outside clinical trials. Any future approval would depend on larger studies confirming safety and benefit.
The takeaway
Early results suggest gene-edited CAR-T cells may help some patients with difficult autoimmune diseases, but the sample sizes are small. Larger trials will be needed before any conclusions about benefit and safety can be drawn.
Further reading
For related coverage, explore Biotech developments in gene editing and cell therapy.
More information
Learn more on the CRISPR Therapeutics company website.
Source note: This article includes information reported by The Manila times.
